BM-1244 (APG-1252-M1) is a potent Bcl-xL/Bcl-2 inhibitor with K i s of 134 and 450 nM for Bcl- xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC 50 of 5 nM. (From patent WO2019033119A1).
性状
Solid
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Jill Hopkins, et al. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells. WO2019033119A1.[2]. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333(2):336-343.
溶解度数据
In Vitro: DMSO : 200 mg/mL (172.45 mM; Need ultrasonic)配制储备液
[1]. Jill Hopkins, et al. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells. WO2019033119A1.[2]. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333(2):336-343.